Exosomal miR-221-3p Derived from Bone Marrow Mesenchymal Stem Cells Alleviates Asthma Progression by Targeting FGF2 and Inhibiting the ERK1/2 Signaling Pathway

Figure 6

The exosomal miR-221-3p derived from BMSCs alleviated asthma progression in mice. BALB/c mice were randomly divided into three groups (n = 8 per group): control group, OVA group, and OVA + Exo group. OVA-induced asthmatic mice model was constructed, and exosomal miR-221-3p was injected for treatment. (a) The expression of miR-221-3p in lung tissues of mice was measured by using RT-qPCR. (b), (c) The expression of FGF2 protein in lung tissues of mice was detected by using Western blot analysis. (d) The airway hyperresponsiveness of mice in all groups was detected. (e), (f) Histopathological evaluation of lung tissue sections from each group were detected by HE staining and Masson staining, and significant histopathological changes were marked with an arrow. (g) The number of total and differential inflammatory cells in BALF. (h) The serum OVA-specific IgE levels of mice in all groups were detected by using ELISA.(i) The levels of TGF-β1, IL-4, and IL-13 in BALF were examined by using ELISA. Data from at least three independent experiments were presented as mean ± SD .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)